Tq3000
Posted - 6 hours ago
$BEAM LONG adding position below $25 average
BarneyR
Posted - 11 hours ago
$BEAM $EDIT $NTLA $CRSP $VERV The assholes are now in full regalia. Taking advantage of low volume to drive the whole gene therapy sector down.
BarneyR
Posted - 11 hours ago
$CRSP $BEAM $EDIT $NTLA $VERV The scummy crew showed up early today, 3 minutes in. Usually they'll give in 15 or 20 minutes before they launch their little games. Concerned that gene therapy shares are gaining momentum?
BarneyR
Posted - 2 days ago
$CRSP $BEAM $NTLA $VERV $EDIT Scummy MMs and their hedgefund pals brought their algos to the party, itching to shit in the punchbowl.
BeenHereTooLong
Posted - 2 days ago
$BLUE Damn when every gene editing company like $CRSP $NTLA or $BEAM is up 8%+. Leave it to good old penny stock bluebird bio to take a -3% shitter. It's almost as if it's not a gene editing company at all. And almost as if it'll be delisted / reverse split within the next 90 days.
DNAedit
Posted - 3 days ago
$BEAM see you on Friday at $21 and change. Holding this for the few big up days in the next few years is a big miss. You could just put money in nividia and coast.
HarryScrotmsRashy
Posted - 3 days ago
$BEAM Let's get back to $40.
_StockTrader
Posted - 3 days ago
Real-Time Stock Data $BEAM
Price: 23.96
Volume: 1010670
Market Cap: 1963943040
PE Ratio: -5.0020967
Powered by: AITX
Jdolan99
Posted - 3 days ago
@MF__DOOM I don’t know who taught you math, but when a company has extremely little money, they have no way to make money and they’ve already diluted so many times that nobody trusts them not to do it again and again, they very well are a bankruptcy risk. Nobody is going to buy a company for an SCD treatment that will be obsolete by 2028/2030 when BEAM-101 hits the market. Already second best option behind $CRSP, soon to be third best behind $EDIT, then fourth best behind $BEAM. Not enough meat on the bone for anyone to take the risk on. People have been preaching “buyout next month” since the share price was north of $100.
HarryScrotmsRashy
Posted - 3 days ago
$BEAM picked up BEAM today hope the gene editing correction is over.
GeneInvestingTwitter
Posted - 4 days ago
$CRSP $NTLA $BEAM TOP 5 STORIES this week ⬇️ Posted on X.
GeneInvestingTwitter
Posted - 6 days ago
$NTLA $BEAM $CRSP First decent move in awhile… Sold 300 $NTLA despite loving their earnings call for 342 $BEAM Now at… 3867 $BEAM 3000 $NTLA NEW TOTAL: 6867 shares $500,000 number: $72.81 (was $73.26) This is simply a trade to pick up extra shares. I don’t see myself going under 3,000 $NTLA and this allows me to trade back if the prices flip again.
BarneyR
Posted - 6 days ago
$BEAM Hey scummy MMs, you can take it down $1 every day for the next month and it'll be close to zero. You'll be heroes to all the shorts and hand them their wet dream, a busted biotech, destroyed while trying their damndest to cure disease. No worries, there's plenty of other companies who'll be there to pick up the business and all Beam's best employees. You go shorts, your mission to profit off of misery is a righteous one. Hope you get enough to buy that third vacation property.
PorkyPig
Posted - 6 days ago
$BEAM Oh! that was totally unnecessary. Mamma Cathie getting redemptions or something?
BarneyR
Posted - 6 days ago
$BEAM Reached nearly 50 points 10 weeks ago, now closing in on being worth 1/3 of that. Wall Street gambling hall where every table is controlled by the market makers, designed to rob willing rubes of their wages.
BarneyR
Posted - 6 days ago
$BEAM Wall Street scumbags doing their Friday hustle. BEAM now 2+ points under NTLA. Huh?
classhopper
Posted - 6 days ago
$BEAM going nowhere fast Just sayin
GeneInvestingTwitter
Posted - 1 week ago
$NTLA my review of the Q1 Earnings Report/Call is now live with my grading on each area of the company broken down, one by one. Come check it out! $BEAM $EDIT $CRSP
BarneyR
Posted - 1 week ago
$BEAM $EDIT $NTLA $CRSP $VERV Scumbags squeezing retail for shares. Low pieces of trash, these MMs.
Blizzy
Posted - 1 week ago
$BEAM thoughts on averaging down here to get basis to $42?
Jdolan99
Posted - 1 week ago
@GeneInvestingTwitter I’m currently 55/35/10 $NTLA / $BEAM / $CRSP. I feel safer about Intellia in the short term (risk of dilution and time to approval) but see Beam having more potential in the long run, especially with IP licensing. Holding a small Crispr Tx position simply because I see them as greatly undervalued on short term SCD market alone. Would your recommendation be to balance out and add more Beam at these current levels or stick with a higher Intellia split? I know you’re about 50/50 so I’m assuming the former. Will only be adding Intellia and Beam for the foreseeable future. Thanks for any advice! (I am only 24yo so timeline is of no real concern).
russellkbrett
Posted - 1 week ago
@nrp You'd never know $BEAM even reported this morning looking at the anemic volume over there. Did well over 7M total on the last report (Feb 27th). That stock still has more than 13M shares held short and is not even doing 1M total volume today. Share price was cut in half from the highs of the last ER. My take is that too much of the floats now are held short within the entire group ($CRSP $EDIT $PRME VERV CRBU) that there's not enough available shares in the daily churn to provide the liquidity needed to cover all without moving the price up substantially. Would be nice to see a big open sustain an upside momentum in order to get them more motivated.
nrp
Posted - 1 week ago
$EDIT $Beam reported and stock has performed very well. I feel comfortable with tomorrows report. I added more today.
PorkyPig
Posted - 1 week ago
$BEAM Hit me baby one more time. Oh baby, baby How was I supposed to know? https://www.youtube.com/watch?v=SVjgf4n9XWM
DonCorleone77
Posted - 1 week ago
$BEAM Beam Therapeutics reports Q1 EPS ($1.21), consensus ($1.42) Reports Q1 revenue $7.41M, consensus $16.97M. Cash, cash equivalents and marketable securities were $1.1B as of March 31, 2024, compared to $1.2B as of December 31, 2023. "We're pleased to share progress across our high-priority programs that exemplify our commitment to rapid, focused execution and a dedication to developing differentiated, one-time medicines for serious genetic diseases," said John Evans, CEO of Beam. "We have successfully completed dosing and engraftment for three sickle cell disease patients in the sentinel cohort of the BEAM-101 BEACON trial allowing us to now move forward with expansion phase dosing. We look forward to sharing data for multiple patients treated with BEAM-101 later this year. In addition, our team has done an incredible job executing our ex-U.S. clinical strategy for BEAM-302, securing CTA clearance in the UK and rapidly working toward the initiation of our Phase 1/2 trial in patients with alpha-1 antitrypsin deficiency. This study is designed to demonstrate proof-of-concept for correction of the disease-causing mutation that could potentially help patients with both lung and liver disease manifestations. These updates, supported by our robust balance sheet, mark a significant stride toward our goal of establishing base editing as a potentially transformative and differentiated therapeutic option for patients in need."
epsguid
Posted - 1 week ago
$BEAM reported a loss of $1.21, consensus was ($1.45) via @eWhispers #epsbeat http://eps.sh/d/beam
Stock_Titan
Posted - 1 week ago
$BEAM Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
https://www.stocktitan.net/news/BEAM/beam-therapeutics-reports-pipeline-updates-and-first-quarter-2024-agf14i7tc4gg.html
BoeingStingray
Posted - 1 week ago
Participants of pioneering CRISPR gene editing trial see vision improve | OHSU News $Crsp $edit $beam $ntla https://news.ohsu.edu/2024/05/06/participants-of-pioneering-crispr-gene-editing-trial-see-vision-improve
BarneyR
Posted - 1 week ago
$BEAM Shithead MMs and shorts are working hard to keep BEAM and other gene editors down. Are they frightened by what happened the last time BEAM and CRSP reported?
